{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:40:34Z","timestamp":1791319234045,"version":"4.3.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Sodium zirconium cyclosilicate (SZC) reduces serum potassium in patients with chronic hyperkalaemia in clinical trials, but its role in the emergency treatment of hyperkalaemia is unproven. We hypothesized that SZC use for emergent hyperkalaemia would be associated with a reduction in rates of emergency interventions for hyperkalaemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a single-centre, propensity score\u2013weighted case\u2013control study of patients admitted with hyperkalaemia to a specialist renal centre. We randomly selected 250 patients admitted between April 2021 and September 2022 (post-SZC era) with a potassium level \u22655.5\u00a0mmol\/l treated with at least one \u226510\u00a0g dose of SZC (treatment group). We randomly selected a comparator group of 250 patients admitted between January 2018 and December 2019 (pre-SZC era) with a potassium level \u22655.5\u00a0mmol\/l (control group). Baseline demographic and clinical characteristics were recorded and used as covariates for propensity scoring and inverse probability treatment weighting (IPTW). Our primary outcome measure, rates of emergency haemodialysis (HD), was tested using unadjusted models and multivariable logistic regression models on unweighted data in addition to unadjusted models on weighted data. We also reviewed rates of emergency temporary central venous access as a secondary outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 59% were male, the mean age was 67\u00a0years (standard deviation 14) and 149 (30%) were receiving maintenance dialysis. IPTW achieved satisfactory balance of covariates between the treatment and control groups. In the treatment group, patients were 77% less likely to need emergency HD {odds ratio [OR] 0.23 [confidence interval (CI) 0.17\u20130.31]}. This result was consistent following analysis of weighted and unweighted data. Similarly, patients treated with SZC were 73% less likely to require emergency temporary central venous access [OR 0.27 (CI 0.20\u20130.36)].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>SZC was associated with a significant reduction in the rates of emergency HD and emergency temporary central venous access in patients admitted to a specialized renal centre with emergent hyperkalaemia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfae313","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T08:01:49Z","timestamp":1729584109000},"source":"Crossref","is-referenced-by-count":5,"title":["Sodium zirconium cyclosilicate treatment and rates of emergency interventions for hyperkalaemia: a propensity\u2013score weighted case\u2013control study"],"prefix":"10.1093","volume":"17","author":[{"given":"William R","family":"Marshall","sequence":"first","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel A","family":"Curran","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie P","family":"Traynor","sequence":"additional","affiliation":[{"name":"Glasgow Renal and Transplant Unit, NHS Greater Glasgow and Clyde , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A","family":"Gillis","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-2123","authenticated-orcid":false,"given":"Patrick B","family":"Mark","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6331-0178","authenticated-orcid":false,"given":"Jennifer S","family":"Lees","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"2024112912183188800_bib1","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.ajkd.2019.03.427","article-title":"Physiology and Pathophysiology of potassium homeostasis: Core Curriculum 2019","volume":"74","author":"Palmer","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2024112912183188800_bib2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.5414\/CN108628","article-title":"Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study","volume":"85","author":"Hagan","year":"2016","journal-title":"Clin Nephrol"},{"key":"2024112912183188800_bib3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/01.JAA.0000458856.92020.1e","article-title":"Hyperkalemia and potential pitfalls of sodium polystyrene sulfonate","volume":"28","author":"Nguyen","year":"2015","journal-title":"JAAPA"},{"key":"2024112912183188800_bib4","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1001\/jamainternmed.2019.0631","article-title":"Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age","volume":"179","author":"Noel","year":"2019","journal-title":"JAMA Intern Med."},{"key":"2024112912183188800_bib5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1681\/ASN.2010010079","article-title":"Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?","volume":"21","author":"Sterns","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2024112912183188800_bib6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/ndt\/gfaa229","article-title":"Adverse gastrointestinal events with sodium polystyrene sulphonate and calcium polystyrene sulphonate use in dialysis patients: a nationwide registry study","volume":"36","author":"Ferreira","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2024112912183188800_bib7","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1056\/NEJMe1414112","article-title":"A new era for the treatment of hyperkalemia?","volume":"372","author":"Ingelfinger","year":"2015","journal-title":"N Engl J Med"},{"key":"2024112912183188800_bib8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N Engl J Med"},{"key":"2024112912183188800_bib9","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"2024112912183188800_bib10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.mayocp.2019.05.019","article-title":"Potassium binders for hyperkalemia in chronic kidney disease\u2014diet, renin\u2013angiotensin\u2013aldosterone system inhibitor therapy, and hemodialysis","volume":"95","author":"Palmer","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2024112912183188800_bib11","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2024112912183188800_bib12","volume-title":"Sodium zirconium cyclosilicate (SMC 2288)","author":"Scottish Medicines Consortium","year":"2020"},{"key":"2024112912183188800_bib13","volume-title":"Sodium zirconium cyclosilicate for treating hyperkalaemia. TA599","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"2024112912183188800_bib14","volume-title":"Renal Association clinical practice guidelines: treatment of acute hyperkalaemia in adults","author":"UK Kidney Association","year":"2020"},{"key":"2024112912183188800_bib15","volume-title":"Clinical practice guidelines: treatment of acute hyperkalaemia in adults","author":"UK Kidney Association","year":"2023"},{"key":"2024112912183188800_bib16","author":"Scottish Medicines Consortium","year":"2022","journal-title":"Sodium zirconium cyclosilicate (SMC 2515)"},{"key":"2024112912183188800_bib17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2024112912183188800_bib18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/MEJ.0000000000000691","article-title":"Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference","volume":"27","author":"Lindner","year":"2020","journal-title":"Eur J Emerg Med"},{"key":"2024112912183188800_bib19","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/ckj\/sfaa242","article-title":"Pharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome them","volume":"14","author":"Fu","year":"2020","journal-title":"Clin Kidney J"},{"key":"2024112912183188800_bib20","first-page":"13","article-title":"A practical guide for using propensity score weighting in R","volume":"20","author":"Olmos","year":"2015","journal-title":"Pract Assess Res Eval."},{"key":"2024112912183188800_bib21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"key":"2024112912183188800_bib22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/acem.13954","article-title":"Emergency potassium normalization treatment including sodium zirconium cyclosilicate: a phase II, randomized, double-blind, placebo-controlled study (ENERGIZE)","volume":"27","author":"Peacock","year":"2020","journal-title":"Acad Emerg Med"},{"key":"2024112912183188800_bib23","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s10157-020-01937-1","article-title":"Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2\/3 study","volume":"24","author":"Kashihara","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"2024112912183188800_bib24","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJMra011883","article-title":"Preventing complications of central venous catheterization","volume":"348","author":"McGee","year":"2003","journal-title":"N Engl J Med"},{"key":"2024112912183188800_bib25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2215\/CJN.05260516","article-title":"Diagnosis, treatment, and prevention of hemodialysis emergencies","volume":"12","author":"Saha","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024112912183188800_bib26","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2020.11.024","article-title":"Hemodialysis emergencies: Core Curriculum 2021","volume":"77","author":"Greenberg","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2024112912183188800_bib27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2021.09.018","article-title":"Clinical outcomes associated with the emergency treatment of hyperkalaemia with intravenous insulin-dextrose","volume":"95","author":"Humphrey","year":"2022","journal-title":"Eur J Intern Med"},{"key":"2024112912183188800_bib28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/cen.14343","article-title":"Iatrogenic hypoglycaemia following glucose-insulin infusions for the treatment of hyperkalaemia","volume":"94","author":"Tee","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024112912183188800_bib29","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12882-022-02903-7","article-title":"Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden","volume":"23","author":"Kim","year":"2022","journal-title":"BMC Nephrol"},{"key":"2024112912183188800_bib30","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1093\/ndt\/gfm870","article-title":"The cost of renal dialysis in a UK setting\u2014a multicentre study","volume":"23","author":"Baboolal","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2024112912183188800_bib31","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/08968608211061126","article-title":"Current costs of dialysis modalities: a comprehensive analysis within the United Kingdom","volume":"42","author":"Roberts","year":"2022","journal-title":"Perit Dial Int"},{"key":"2024112912183188800_bib32","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2024112912183188800_bib33","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2024112912183188800_bib34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12882-023-03145-x","article-title":"A randomized study to compare oral potassium binders in the treatment of acute hyperkalemia","volume":"24","author":"Ca\u00f1as","year":"2023","journal-title":"BMC Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae313\/59934983\/sfae313.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/11\/sfae313\/60899223\/sfae313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/11\/sfae313\/60899223\/sfae313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T12:18:46Z","timestamp":1732882726000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae313\/7829284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae313","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,10,21]]},"article-number":"sfae313"}}